Oncorus
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
Oncorus developed cancer treatments using engineered viruses and self-amplifying RNA.
02 / Oncorus FAILURE REASONS
Failure reasons
The board cited difficulty raising further capital under prevailing market conditions. After discontinuing a drug program and reducing staff, it explored strategic alternatives but proceeded to dissolution and liquidation as its expected cash runway shortened.
03 / EVENT HISTORY
Events in the structured record
- Program discontinued
In November the company discontinued its herpes-virus drug program and cut staff.
- Large workforce reduction
On 1 June the company announced extensive layoffs.
- Board approved dissolution plan
On 6 June the board approved liquidation and dissolution subject to shareholder approval. Approval of a plan is distinct from completed dissolution.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
Further capital difficult to obtain
- 02
Cash runway shortened
- 03
Strategic alternatives explored
- 04
Dissolution and liquidation approved